Balyasny Asset Management LLC Candel Therapeutics, Inc. Transaction History
Balyasny Asset Management LLC
- $72.4 Billion
- Q3 2025
A detailed history of Balyasny Asset Management LLC transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 49,483 shares of CADL stock, worth $228,116. This represents 0.0% of its overall portfolio holdings.
Number of Shares
49,483Holding current value
$228,116% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding CADL
# of Institutions
87Shares Held
14.9MCall Options Held
313KPut Options Held
127K-
Acorn Capital Advisors, LLC New York, NY2.58MShares$11.9 Million6.68% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.01MShares$9.25 Million0.0% of portfolio
-
Northpond Ventures, LLC1.94MShares$8.92 Million48.35% of portfolio
-
Portolan Capital Management, LLC Boston, MA1.38MShares$6.38 Million0.45% of portfolio
-
Geode Capital Management, LLC Boston, MA928KShares$4.28 Million0.0% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $133M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...